Lakewood-Amedex Biotherapeutics Inc. 8K

Lakewood-Amedex Biotherapeutics Inc. furnished an investor deck outlining its Bisphosphocin antimicrobial platform, lead Nu-3 Phase 2 program for infected diabetic foot ulcers, development milestones, IP position, and management team.

Lakewood-Amedex Biotherapeutics Inc. furnished an investor presentation dated July 15, 2026 describing its clinical-stage biotechnology activities focused on its patented Bisphosphocin class of fast-acting, broad-spectrum antimicrobial compounds, highlighting lead candidate Nu-3 as a topically delivered gel for infected diabetic foot ulcers with an open and active IND and an upcoming FDA-aligned Phase 2a/2b clinical program in the U.S., associated development timelines and milestones through 2027, an expanded early-stage pipeline, a robust global intellectual property portfolio with patent protection extending into the 2040s, and details on its management team and competitive positioning in addressing antimicrobial resistance.

Filing Facts

CIK

2079272

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-078328

Alert Tier

5